FDA approves belzutifan for advanced renal cell carcinoma
On December 14, 2023, the Food and Drug Administration approved belzutifan (Welireg, Merck& Co., Inc.) for patients with advanced renal cell carcinoma (RCC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 14, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Telix highlights first patient dosed with new renal cancer PET agent
Telix Pharmaceuticals is highlighting that the first patient has been dosed with the company's TLX250-CDx (Zr-89 DFO-girentuximab) for clear cell renal cell carcinoma, the most common and aggressive form of kidney cancer.The patient program is being conducted at Radboud University Medical Centre in Nijmegen, the Netherlands, and follows the completion of Telix's phase III ZIRCON study (Zirconium in Renal Cancer Oncology) which reported positive results, according to the firm.Telix is moving forward toward completing a Biologics License Application submission for TLX250-CDx with the U.S. Food and Drug Administration, it...
Source: AuntMinnie.com Headlines - December 4, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Subspecialties Nuclear Radiology Source Type: news
AI algorithm helps determine status of small renal lesions
CHICAGO -- A deep-learning AI algorithm designed to determine the malignancy status of renal lesions less than 4 cm could reduce overtreatment and undertreatment of kidney cancer, according to research presented November 26 at RSNA 2023.The AI functions by taking a preoperative CT scan as input, localizes the tumor region by segmenting it, and then predicts the probability of malignancy in a fully automated fashion, according to Aakanksha Rana, PhD, of Johnson & Johnson in New Brunswick, NJ.“The outcome was good given our small dataset,” Rana said, adding that there is much work to be done. “It’s very surprising to...
Source: AuntMinnie.com Headlines - November 26, 2023 Category: Radiology Authors: Liz Carey Tags: Resources Conference RSNA 2023 Source Type: news
Treatment of Favorable-Risk Advanced Renal Cell Carcinoma Treatment of Favorable-Risk Advanced Renal Cell Carcinoma
Experts discuss strategies for treating patients with favorable-risk advanced renal cell carcinoma in light of IMDC guidelines and recent prospective studies.Medscape (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 17, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
'We're Not There Yet': CAR T-Cell Therapy for Renal Cell Carcinoma
(MedPage Today) -- NASHVILLE, Tenn. -- Chimeric antigen receptor (CAR) T-cell therapy has the potential to become standard-of-care therapy for renal cell carcinoma (RCC) that does not respond to current therapies, an RCC specialist said here... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 16, 2023 Category: Hematology Source Type: news
Targeting New Pathways to Improve Outcomes in Renal Cell Carcinoma
(MedPage Today) -- NASHVILLE, Tenn. -- Building on the existing immune checkpoint inhibitor (ICI) platform, new treatment strategies for renal cell carcinoma (RCC) seek to adapt the cancer's immunity cycle to inform development of more effective... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 15, 2023 Category: Hematology Source Type: news
Renal Cell Carcinoma Highlights From ESMO 2023 Renal Cell Carcinoma Highlights From ESMO 2023
Dr Brian Rini reviews key studies on renal cell carcinoma from ESMO 2023, including several LITESPARK trials examining belzutifan, and the RENOTORCH trial from China looking at a IO/TKI combination.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 14, 2023 Category: Consumer Health News Tags: None ReCAP Source Type: news
No Boost in Outcomes for Clear Cell RCC With Higher Belzutifan Dose
(MedPage Today) -- NASHVILLE, Tenn. -- A higher dose of belzutifan (Welireg) being investigated for advanced clear cell renal cell carcinoma (ccRCC) did not improve outcomes as compared with the usual dose in other settings, a randomized trial... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 13, 2023 Category: Hematology Source Type: news
Tyrosine Kinase Inhibitor Active in Heavily Treated Renal Cell Carcinoma
(MedPage Today) -- NASHVILLE, Tenn. -- An investigational multitargeted drug produced objective responses in clear-cell renal cell carcinoma (ccRCC), irrespective of prior exposure to cabozantinib (Cabometyx), a small clinical trial showed.... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 12, 2023 Category: Hematology Source Type: news
Morphologic features on sonography predict metastasis
Morphologic features of axillary nodes on sonography are reliable indicators in predicting metastasis, according to research published October 24 in Clinical Imaging.
A team led by Anubha Wadhwa, MD, from Froedtert Hospital in Milwaukee, WI, found that greater cortical thickness and the absence of a normal hilum had the highest positive predictive value (PPV) for metastatic disease.
“Using clinical history in conjunction with imaging findings will help improve the accuracy of axillary nodal biopsies, especially for incidental nodes detected on screening,” the Wadhwa team wrote.
Predicting axillary nodal status is ...
Source: AuntMinnie.com Headlines - October 26, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Ultrasound Source Type: news
Survival Improved With Everolimus in High-Risk Clear Cell Renal Cancer
MONDAY, Oct. 23, 2023 -- For patients with clear cell renal cell carcinoma (RCC) at very high risk for recurrence, adjuvant everolimus is associated with significantly improved recurrence-free survival, according to a study presented at the annual... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 23, 2023 Category: Pharmaceuticals Source Type: news
Renal Cell Carcinoma: 5 Things to Know for Primary Care Renal Cell Carcinoma: 5 Things to Know for Primary Care
Cues and clues to renal cell cancer might be found in modifiable or innate patient factors. These 5 things to know for primary care might tip off timely testing or a potentially life-saving referral.Medscape Family Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 11, 2023 Category: Consumer Health News Tags: Family Medicine/Primary Care Commentary Source Type: news
SABR Offers New Hope for Older Patients With Inoperable Kidney Cancer
(MedPage Today) -- SAN DIEGO -- Stereotactic ablative body radiotherapy (SABR) was an effective, noninvasive strategy for treating primary renal cell carcinoma (RCC) in patients who were not suitable for surgery, according to the FASTRACK II... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 2, 2023 Category: Hematology Source Type: news
S2 Episode 6: Neoadjuvant Therapy and Renal Cell Carcinoma S2 Episode 6: Neoadjuvant Therapy and Renal Cell Carcinoma
Drs Sumanta Pal and Jose A. Karam discuss neoadjuvant therapy in renal cell carcinoma, including TKIs, IO, and the need for more studies to explore the role of neoadjuvant therapy in RCC.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 7, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
Ray Trapp: Build resilience to meet life's challenges
13 months from the diagnosis of stage three renal cell carcinoma and I sit here in awe of the audacity of resilience. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 13, 2023 Category: Pharmaceuticals Authors: Ray Trapp Source Type: news
